Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
NCT ID: NCT05751720
Last Updated: 2024-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2023-10-01
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Non-alcoholic fatty liver disease is present in more than 30% of patients with type 2 diabetes and in \> 50% patient with obesity
20% of patients with Non-alcoholic fatty liver disease progress to develop non-alcoholic steatohepatitis which can lead to liver failure and hepatocellular carcinoma.
This study aims to use GLP-1 analogue to see effects on liver fat deposition after six months of treatment
There is no current randomised study on treatment of non-alcoholic steatohepatitis in United Arab Emirates population; so once completed this will the first study.
This study will pave the way for developing a treatment pathway for patients with non-alcoholic fatty liver disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
NCT05644717
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
NCT06117137
A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
NCT03357380
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
NCT05147090
GLP-1 RA on Liver OMICS in MASLD
NCT06982378
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Over the past few decades Non-Alcoholic Fatty liver disease (NAFLD) related non-alcoholic steatohepatitis (NASH) cirrhosis has overtaken all other causes of liver cirrhosis in the developed world, secondary to the rising epidemic of obesity and type 2 Diabetes mellitus. The prevalence of NAFL is estimated at 30% in developed work and nearly one fifth of them NFALD will progress to NASH, 20% of which will develop liver cirrhosis subsequently leading to liver failure and hepatocellular carcinoma (HCC). Annual medical costs directly attributed to NAFLD exceed €35 billion in top European countries (United Kingdom, France, Germany, and Italy) and over $100 billion in the United States, while cost of this in unknown in Middle East. Non-alcoholic fatty liver disease (NAFLD) is defined as fatty infiltration of the liver not related to alcohol excess or other usual causes of hepatic steatosis (e.g. viral or autoimmune hepatitis or secondary to medications) and includes a spectrum ranging from steatosis, steatohepatitis, and fibrosis to cirrhosis; it is now the most common cause of chronic liver disease worldwide. Although most patients with NAFLD may not progress to advanced fibrosis or cirrhosis, due to the high prevalence the number of patients develop cirrhosis is still high and is now a leading indication for liver transplantation in Europe. Global prevalence data for NAFLD suggest that the, Midlle East region has one of the highest prevalence rate of up to 32%.Type 2 diabetes mellitus (T2DM) is an important risk factor for non-alcoholic fatty liver disease (NAFLD) with recent metanalysis showing that the global prevalence of NAFLD among patients with T2DM to be around 55.5% with no specific available data for Emirati population with respects to NAFLD in T2DM patients. Obesity is another well-known risk factor and there is high prevalence of NAFLD in obese patients, with up to 65% of people with grade I-II obesity (BMI = 30-39.9 kg/m2) and in 85% of patients with grade III obesity (BMI = 40-59 kg/m2) having NAFLD.
United Arab Emirates (UAE) has one of the highest prevalence of type 2 Diabetes Mellitus in the world with 16.4% of adult population diagnosed with this condition as per International Diabetes federation. UAE also has the highest prevalence of obesity, doubled from 1989 to 2017, currently ranking among the top 40 countries in the world with estimated prevalence rate of 31.7%, using body mass index (BMI) cut-off of 30 kg/m2. This rate will be substantially higher if newer definition of ethnicity specific BMI cut off for obesity (i.e. \> 25 kg/m2 being obese) is used, which is more relevant for Asian population. The presence of both these conditions means UAE is likely to have very high prevalence of NAFLD in patients having both diabetes and obesity.
The gold standard test for identifying NALFD and Non-alcoholic steatohepatitis (NASH) is a liver biopsy. However, liver biopsy is an invasive procedure and is associated with complications. A non-invasive method using Vibration-controlled transient elastography (VCTE) utilizing FibroScan provides a liver stiffness measurement (LSM) expressed in kilopascals (kPa) which correlate with fibrosis advanced stages like F3 (bridging fibrosis) with LSM of 9.9-13.9 KPa and F4 (advanced scarring or cirrhosis) quite well and has emerged as an alternative to invasive liver biopsy. Other non-invasive tools used to detect the presence of advanced fibrosis in NAFLD include clinical/biochemical scoring systems like NAFLD fibrosis score (NFS) and FIB-4 index, aspartate aminotransferase (AST) to platelet ratio index (APRI), Enhanced Liver Fibrosis panel, Hepascore; and imaging techniques like VCTE or magnetic resonance elastography(MRE). The NFS is based on six clinical/biochemical variables including age, presence of impaired fasting glucose or Diabetes, Body Mass Index (BMI), platelet count, albumin and AST/ALT (alanine aminotransferase) ratio. A recent large meta-analysis, showed that NFS had an area under the receiver operating curve (AUROC) of 0.85 for predicting advanced fibrosis stages like F3 (bridging fibrosis) and F4 (advanced scarring or cirrhosis) with a score of 0.676 or more having 67% sensitivity and 97% specificity to identify the presence of advanced fibrosis. A recent study that compared various risk scores and elastography (including MRE and VCTE) versus liver histology to identify NAFLD fibrosis showed that NFS were better than other indices such as BARD, APRI, and AST/ALT ratio; and found to be as good as MRE and and FIB-4 for predicting advanced fibrosis in patients with biopsy-proven NAFLD. Recent guidelines therefore recommend NFS as a clinically useful tool for identifying patients with NAFLD with a higher likelihood of having advanced fibrosis (F3 or F4).
Currently various treatments have been used for NALFD. The current guidelines from American Association for study of liver diseases suggests that Pioglitazone can improve histological appearance in patient with type 2 Diabetes Mellitus and NASH while Vitamin E may offer benefit in non-diabetic population, while GLP-1 Analgoues like liraglutide could be beneficial however there is not enough evidence for it to be used routinely for patients with NASH.
There is no current data on use of Tirzepatide with NAFLD in Emirati population. There is no literature, to the best of authors knowledge. This study offers our centre and UAE university to be first in the world to trial this study without any known risks and publish new and unique data.
The aim of this study to assess the effects of GLP-1 analogues (subcutaneous Tirzepatide or oral semaglutide) in reducing the fat content and Liver stiffness (using non-invasive imaging methods) in patients with established advanced liver fibrosis with type 2 Diabetes Mellitus in local population.
Specific Aims:
Primary Aim:
To see if GLP-1 analogue causes reduction in liver fat on imaging in patient with type 2 Diabetes Mellitus and NAFLD in our population
Secondary Aims To assess any changes in liver function tests/biochemical profile To see improvement in in NAFLD fibrosis score and it relation to liver fat measurement To see improvement in physical parameters such as weight, BMI, blood pressure To see improvement in blood glucose, HbA1c To assess any reported side effects or tolerability of this combination in local population
Methods, Specific Tasks and Time Schedule:
STUDY DESIGN It is Prospective open label randomized study of adult patients with type 2 diabetes mellitus attending Tawam Hospital Diabetes clinic meeting the selection criteria as below
DATA COLLECTION:
The adult patients with type 2 diabetes mellitus attending Tawam Hospital Diabetes clinic, who are identified as having fatty liver disease either via ultrasound or biochemical parameter of NFS. . The NAFLD fibrosis score (NFS) will be calculated using the published formula (available at website http://gihep.com/calculators/hepatology/nafld-fibrosis-score/).
The investigators will aim to include minimum 30 patients fulfilling the selection criteria as below. Informed written consent will be obtained and the group will receive GLP-1 analogues (subcutaneous Tirzepatide or oral semaglutide). The dose of oral semaglutide will be 3 mg daily for 30 days (initiation) and if dose then increased to 7 mg daily for 6 months while the dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly. The blood tests will be done at baseline, 3 months of treatment and at 6 months of treatment. Liver imaging (fibroscan and/or MRI fat measurement) will be done at baseline and at 6 months to see if there is any change.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GLP-1/GIP Arm pre and post intervention
The adult patients with type 2 diabetes mellitus attending Tawam Hospital Diabetes clinic, who are identified as having fatty liver disease either via ultrasound or biochemical parameter of NFS.
We will aim to include minimum 30 patients fulfilling the selection criteria as below. Informed written consent will be obtained . Intervention group will receive GLP-1 analogues (subcutaneous Tirzepatide or oral semaglutide).
The blood tests will be done at baseline, 3 months of treatment and at 6 months of treatment. Liver imaging (fibroscan and/or MRI fat measurement) will be done at baseline and at 6 months to see if there is any change.The KPa improvement in liver stiffness and total fat estimation pre and post intervention in both groups will assessed
GIP/GLP-1a
The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GIP/GLP-1a
The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed to have Type 2 Diabetes Mellitus for \> 1 year.
* Presence of NAFLD advanced fibrosis (F3 and F4; defined by NFS of \> 0.676)
* Able to consent independently
* Not already on GLP-1 analogues or SGLT2 inhibitors or pioglitazone
* Good general health
* BMI\> 19 but less than 40
Exclusion Criteria
* Evidence of pre-existing liver or biliary disease (hepatoma, biliary tract obstruction; liver cirrhosis secondary to viral infection or immune/ congenital).
* Known or suspected hypersensitivity to GLP-1 analogues or pioglitazone.
* Receipt of any investigational medicinal product within 30 days before screening.
* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods.
* Endocrinopathies (e.g., Cushing syndrome)
* Personal history of heart disease especially heart failure
* History of malignant neoplasm within 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ is allowed.
* eGFR \< 30
* history of heamturia or bladder cancer
* history of osteoporosis
* ALT ≥3.5 times the upper normal limit (UNL)
* Taking steroids, antipsychotics or progesterone preparations
* Uncontrolled hypertension
* Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies.
* HbA1c \> 10%
* Claustrophobia or unable to get MRI due to contraindications (e.g metal in the body)
* Weight \> 150 kg (due to imaging trolley restrictions)
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr Adnan Agha
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Adnan Agha
Assistant Professor, Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adnan Agha, FRCP
Role: PRINCIPAL_INVESTIGATOR
United Arab Emirates University, College of Medicine & Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Internal Medicine, College of Medicine and Health Sciences
Al Ain City, Abu Dhabi Emirate, United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, Fujita K, Yoneda M, Taguri M, Hyogo H, Sumida Y, Ono M, Eguchi Y, Inoue T, Yamanaka T, Wada K, Saito S, Nakajima A. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology. 2016 Mar;150(3):626-637.e7. doi: 10.1053/j.gastro.2015.11.048. Epub 2015 Dec 8.
Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016 May;61(5):1356-64. doi: 10.1007/s10620-016-4079-4. Epub 2016 Mar 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UAEU_CMHS_IM_startup_AA01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.